Joseph M Miller
CIK 1746372 · Chief Financial Officer · last filed 2026-10-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AUPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
#140, 14315-118 AVENUE
EDMONTON T5L 4S6
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LBRX | Chief Financial Officer | — | $39.19 | — | $0 | 1 | 2026-10-13 |
| AUPH | Chief Financial Officer | 613,932 | $17.02 | $10.45M | -$1.36M | 10 | 2026-03-03 |
| AVTX | Director | — | $7.37 | — | $0 | 3 | 2022-04-04 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Director | 40,582 | $2.93 | $118.9K | $10.8K | 13 | 2021-07-02 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | Chief Financial Officer | 45,000 | — | — | $0 | 1 | 2018-07-16 |
Recent Filings · Page 2 of 3
29 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-04-04 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2022-03-04 | AUPH | Mixed | +5,440 | -$36.8K | EDGAR |
| 2022-01-04 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2021-10-04 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2021-07-02 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-17 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-11 | AUPH | Buy (P) | +1,000 | $9.7K | EDGAR |
| 2021-04-02 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-05 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-10-01 | Avalo Therapeutics, Inc. (CERC) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.